Temozolomide
- Generic Name
- Temozolomide
- Brand Names
- Temodar, Temomedac, Temodal, Temozolomide Sun, Temozolomide Accord, Temozolomide Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C6H6N6O2
- CAS Number
- 85622-93-1
- Unique Ingredient Identifier
- YF1K15M17Y
- Background
Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably ...
- Indication
Temozolomide is indicated in adult patients for the treatment of newly diagnosed glioblastoma concomitantly with radiotherapy and for use as maintenance treatment thereafter. It is also indicated for the treatment of refractory anaplastic astrocytoma in adult patients or adjuvant therapy for adults with newly diagnosed anaplastic astrocytoma.
- Associated Conditions
- Advanced Melanoma, High Grade Glioma: Glioblastoma (GBM), Primary Central Nervous System Lymphoma, Refractory Ewing Sarcoma, Refractory Neuroblastoma, Soft Tissue Sarcoma, Advanced Neuroendocrine tumor, Newly diagnosed Anaplastic Astrocytoma (AA), Refractory Anaplastic astrocytoma, Refractory, advanced Mycosis fungoides, Refractory, advanced Sezary Syndrome
- Associated Therapies
- -
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 1672
- Registration Number
- NCT04625907
- Locations
- 🇬🇷
University Unit of Pediatric Oncology-hematology - Children's Hospital Agia Sophia, Athens, Greece
🇮🇱Rambam Health Care Campus, Haifa, Israel
🇮🇱Hadassah University Medical Centre, Jerusalem, Israel
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
- Conditions
- Interventions
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04623931
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Pamiparib in Newly Diagnosed and rGBM
- Conditions
- Interventions
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Nader Sanai
- Target Recruit Count
- 30
- Registration Number
- NCT04614909
- Locations
- 🇺🇸
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
- Conditions
- Clear Cell Papillary Renal NeoplasmHereditary Leiomyomatosis and Renal Cell CarcinomaCollecting Duct CarcinomaMetastatic Unclassified Renal Cell CarcinomaPapillary Renal Cell CarcinomaStage III Renal Cell Cancer American Joint Committee on Cancer (AJCC) v8Unresectable Renal Cell CarcinomaHereditary Papillary Renal Cell CarcinomaMetastatic Renal Cell CarcinomaStage IV Renal Cell Cancer AJCC v8
- Interventions
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT04603365
ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects with Glioblastoma Multiforme
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Polaris Group
- Target Recruit Count
- 100
- Registration Number
- NCT04587830
- Locations
- 🇰🇷
Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanam-do, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of
🇰🇷Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Seocho-gu, Korea, Republic of
Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT04583020
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT04574856
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
ONO-4538 Phase II Rollover Study (ONO-4538-98)
- Conditions
- Interventions
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 59
- Registration Number
- NCT04566380
- Locations
- 🇯🇵
Kanagawa Clinical Site1, Yokohama, Kanagawa, Japan
🇯🇵Tokyo Clinical Site3, Bunkyo-ku, Tokyo, Japan
🇯🇵Chiba Clinical Site2, Chiba, Japan
Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma
- Conditions
- Interventions
- First Posted Date
- 2020-09-18
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT04555577
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2020-09-17
- Lead Sponsor
- Shandong Cancer Hospital and Institute
- Target Recruit Count
- 50
- Registration Number
- NCT04552977
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.